Notice of Intent to Sole Source - M201 ProDrug_Approved for posting 16NOV26.pdf

PDF 126 KB Posted

Attached to
Notice of Intent (NOI) to Sole Source proprietary prodrug MP201 to ISB for testing Acute Stress Reactions (ASRs)
Solicitation number
HT9426-27-NOI-049825
Issued by
Not on record

About this file

This is a Notice of Intent (NOI) to Sole Source a federal contract opportunity.

The Defense Health Agency Contracting Activity (DHACA), on behalf of the Walter Reed Army Institute of Research (WRAIR), Center for Military Psychiatry and Neuroscience (CMPN), Integrative Systems Biology (ISB) Branch, intends to negotiate on a sole source basis with Mitochon Pharmaceuticals, Inc. (970 Cross Lane, Blue Bell, PA 19422-1574) for the supply of two batches of the proprietary prodrug MP201 for testing Acute Stress Reactions (ASRs). The contractor shall deliver freshly synthesized lots of MP201 in dosage quantities ranging from approximately 8-80 mg/kg body weight, formulated for oral administration in mice. The contract also requires the contractor to provide quality control documentation, dosage background information, and informational support to the ISB research team for preparing reports and manuscripts related to MP201. The Product Service Code is AN14 (Health R&D Services; Health Care Services; R&D Administrative Expenses), the NAICS Code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences), and the small business size standard is 1,000 employees.

Responsible and interested parties may submit capability statements in PDF, MS Word, or Excel format by 2:00 p.m. Eastern Time on December 31, 2026, to Herbert Keen (herbert.e.keen.civ@health.mil) and Lance Nowell (lance.l.nowell.civ@health.mil). Submissions must include supporting evidence demonstrating the firm's ability to provide the stated capability. The Government reserves the right to determine whether a competitive procurement is in the best interest of the Government; however, if no responses are received, the DHACA will proceed with the sole source contract award to Mitochon Pharmaceuticals, Inc. Submitted materials will not be returned, and classified material must not be submitted.

View the file

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Notice of Intent (NOI) to Sole Source

Requireing Activity: Walter Reed Army Institute of Research (WRAIR), Center for Military

Psychiatry and Neuroscience (CMPN), Integrative Systems Biology (ISB) Branch

Notice ID – HT9426-27-NOI-049825

Related Notice: N/A

Product Service Code (PSC): AN14 - I HEALTH R&D SERVICES; HEALTH CARE SERVICES;

R&D ADMINISTRATIVE EXPENSES

North American Industry Classification System (NAICS) Code: 541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Small Business Size Standard: 1,000 employees

The Defense Health Agency Contracting Activity (DHACA) on behalf of the WRAIR, CMPN, ISB, intends to negotiate on a sole source basis in accordance with RFO 6.103 with vendor Mitochon

Pharmaceuticals, Inc. 970 Cross Lane, Blue Bell, PA 19422-1574.

The contractor shall supply two (2) Batches of the proprietary prodrug MP201 to ISB for testing Acute

Stress Reactions (ASRs). This includes providing quality control documentation and dosage background information. Additionally, the contractor shall provide informational support to the ISB research team by assisting with preparing reports and manuscripts related to MP201. Each batch of synthesized MP201 shall consist of a freshly made lot of prodrug to determine target dosage in the range of approximately 8 - 80 mg/kg body weight. These doses shall be developed in quantities to support oral administration in mice.

THIS NOI IS NOT A REQUEST FOR COMPETITIVE PROPOSALS, and no solicitation document exists for this requirement. Meaningful submissions received in response to this notice will be considered solely for the purpose of determining whether a competitive procurement is in the best interest of the Government..

Responsible, interested parties may identify their interest by submitting capability statements (using

PDF, MS Word, or Excel attachments), in writing, by 2:00 p.m. Eastern Time, 31 December 2026 to

Herbert Keen at herbert.e.keen.civ@health.mil and Mr. Lance Nowell at lance.l.nowell.civ@health.mil. Supporting evidence must be furnished in sufficient detail to demonstrate the firm’s ability to provide the stated capability. Information and materials submitted in response to theis request WILL NOT be returned. DO NOT SUBMIT CLASSIFIED MATERIAL.

Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the

Government. If no responses are received, the DHACA will proceed with the sole source contract issued to Mitochon Pharmaceuticals, Inc.

mailto:herbert.e.keen.civ@health.mil mailto:lance.l.nowell.civ@health.mil

File details come from the government source that posted it. Updated .